Bone-seeking radionuclides for therapy

Journal of Nuclear Medicine

Volumn 46, Issue 1 SUPPL., 2005, Pages

  Lewington, Val J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Bone pain palliation; Dosimetry; Metastasis; Targeted radionuclide therapy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; ESTRAMUSTINE PHOSPHATE; PHOSPHORUS 32; RADIUM; RADIUM 223; RHENIUM 186; RHENIUM 188; SAMARIUM 153; STRONTIUM 89; TIN 117M; TIN DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ANALGESIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSIMETRY; DRUG HALF LIFE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LEUKOPENIA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; BONE TUMOR; CLINICAL PRACTICE; HEMATOLOGIC DISEASE; METASTASIS; METHODOLOGY; PAIN; PALLIATIVE THERAPY; PATIENT SELECTION; PRACTICE GUIDELINE; RADIATION INJURY; TUMOR RECURRENCE;

ANIMALS; BONE NEOPLASMS; CLINICAL TRIALS; HEMATOLOGIC DISEASES; HUMANS; NEOPLASM RECURRENCE, LOCAL; PAIN; PALLIATIVE CARE; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RADIATION INJURIES; RADIOISOTOPES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 14844361408     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Twycross RG, Fairfield S. Pain in advanced cancer. Pain. 1982;14:303-310.
2. World Health Organization. Cancer Pain Relief and Palliative Care: Report of a WHO Expert Committee. Geneva, Switzerland: World Health Organization; 1990.
3. Body JJ. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer. 2003;97(suppl):859-865.
4. Coleman RE. Optimizing treatment of bone metastases by Aredia™ and Zometa™. Breast Cancer. 2000;7:361-369.
5. Hamdy NA, Papapoulos SE. The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med. 2001;31:62-68.
6. Potsaid M, Irwin R, Castronova F. Phosphorous 32 EHDP clinical study of patients with prostate carcinoma and bone metastases. J Nucl Med. 1976;17:548-549.
7. Nair N. Relative efficacy of P-23 and Sr-89 in palliation in skeletal metastases. J Nucl Med. 1999;40:256-261.
8. Spiers FW, Beddoe AH, King SD. The absorbed dose to bone marrow in the treatment of polycythaemia by P-32. Br J Radiol. 1976;49:133-140.
9. Silberstein EB. The treatment of painful osseous metastases with phosphorus 32 labeled phosphates. Semin Oncol. 1993;3(suppl):10-21.
10. Maxfield JR Jr, Maxfield JGS, Maxfield WS. The use of radioactive phosphorus and testosterone in metastatic bone lesions from breast and prostate. South Med J. 1958;51:320-327.
11. Burnet NG, Williams G, Howard N. Phosphorus 32 for intractable bony pain from carcinoma of the prostate. Clin Oncol. 1990;2:220-223.
12. Silberstein EB, Elgazzar AH, Kapilivsky A. Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases. Semin Nucl Med. 1992;22:17-27.
13. Cheung A, Driedger AA. Evaluation of radioactive phosphorus in the palliation of metastatic bone lesions from carcinoma of the breast and prostate. Radiology. 1980;134:209-212.
14. Ariel IM, Hassouna H. Carcinoma of the prostate: the treatment of bone metastases by radioactive phosphorus. Int Surgery. 1985;70:63-66.
15. Blake GM, Zivanovic MA, Blacquiere RM, Fine DR, McEwan AJ, Ackery DM. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med. 1988;29:549-557.
16. Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. J Nucl Med. 1986;12:447-454.
17. Breen SL, Powe JE, Porter AT. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med. 1992;33:1316-1323.
18. Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 therapy for pain palliation in prostatic skeletal malignancy. Br J Radiol. 1991;64:816-822.
19. McEwan AJB. Palliation of bone pain. In: Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. London, UK: Churchill Livingstone; 1998:1083-1099.
20. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostatic cancer metastatic to bone. Eur J Cancer. 1991;27:954-958.
21. Quilty PM. Kirk D, Bolger JJ, et al. A comparison of the effects of strontium-89 and external beam radiotherapy in metastatic prostatic carcinoma. Radiother Oncol. 1994;31:33-40.
22. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805-813.
23. Smeland S, Erikstein B, Aas M, et al. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double blind randomized study. Int J Radiat Oncol Biol Phys. 2003;56:1397-1404.
24. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43:79-86.
25. Tu SM, Millikan RE, Mengistu B, et al. Bone targeted therapy for advanced androgen independent carcinoma of the prostate: randomised phase II trial. Lancet. 2001;357:336-341.
26. Ackerley W, Butera JM, Wehbe T, et al. A multi-institutional concurrent chemoradiation trial of strontium-89, estramustine and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer. 2002;94:1654-1660.
27. de Klerk JMH, van Dijk A, van Rijk PP, Zonnenberg BA, van het Schip AD. Pharmacokinetics of rhenium-186 after administration of Re-186-HEDP to patients with bone metastases [abstract]. J Nucl Med. 1991;32:1082.
28. de Klerk JMH, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP. Pharmacokinetics of rhenium-186 after administration of Re-186-HEDP to patients with bone metastases. J Nucl Med. 1992;33:646-651.
29. de Klerk JMH, Zonnenberg BA, van het Schip AD, et al. Dose escalation study of Re-186 HEDP in patients with metastatic prostate cancer. Eur J Nucl Med. 1994;21:1113-1120.
30. Maxon HR III, Deutsch EA, Thomas SR, et al. Re-186(Sn)-HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology. 1988;166:501-507.
31. Samaratunga RC, Thomas SR, Hinnefeld JD, et al. A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186(Sn)HEDP. J Nucl Med. 1995;36:336-350.
32. Maxon HR, Schroder LE, Hertzberg VS, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med. 1991;32:1877-1881.
33. 186Re- etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med. 2002;43:1150-1156.
34. de Klerk JMH, van het Schip AD, Zonnenberg BA, van Dijk A, Blijhan GH, van Rijk PP. Phase I study of Re-186-HEDP in patients with bone metastases originating from breast cancer. In: de Klerk JMH. Re-186-HEDP in Treatment of Metastatic Bone Disease: Pharmacokinetics and Toxicity [thesis]. Utrecht, The Netherlands: Universiteit Utrecht, Faculteit Geneeskunde; 1994;81-95.
35. Quirijinen JMSP, Han SH, Zonnenberg BA, et al. Efficacy of rhenium-186 etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med. 1996;37:1511-1515.
36. O'Sullivan JM, McCready VR, Flux G, et al. High activity rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer. 2002;86:1715-1720.
37. de Klerk JMH, Zonnenberg BA, van het Schip AD, et al. Dose escalation study of rhenium-186 hydroxyethylidinediphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med. 1994;21:1114-1120.
38. Zonnenberg BA, de Klerk JMH, van Rijk PP, et al. Re-186 HEDP for treatment of painful bone metastases in patients with metastatic prostate or breast cancer: preliminary results. J Nucl Med. 1999;40:639-642.
39. 188Re-hydroxyethylidenediphosphonate in human prostate cancer skeletal metastases. J Nucl Med. 2003;44:953-960.
40. Palmedo H, Guhlke S, Bender H, et al. Dose escalation study with rhenium-188 hydroxyethylidenediphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med. 2000;27:123-130.
41. Liepe K, Kropp J, Runge R, Kotzerke J. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer. 2003;89:625-629.
42. Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone targeted therapy for hormone refractory prostate carcinoma: randomized phase II trials with the new high-energy radiopharmaceutical rhenium-188 hydroxythylidinediphosphonate. J Clin Oncol. 2003;21:2869-2875.
43. Singh A, Holmes RA, Farhangi M, et al. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med. 1989;30:1814-1818.
44. Faranghi M, Holmes RA, Vorhut Q, Logan K, Singh A. Samarium-153 EDTMP: pharmacokinetics, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med. 1992;33:1451-1458.
45. Ahonen A, Joensuu H, Hiltunen J, et al. Samarium-153-EDTMP in bone metastases. J Nucl Biol Med. 1994;34(suppl):123-127.
46. van Rensburg AJ, Alberts AS, Louw WK. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153 EDTMP. J Nucl Med. 1998;39:2110-2115.
47. Podoloff DA, Kasi LP, Kim EE, Fosella F, Bhadkamar VA. Evaluation of Sm-153 EDTMP as a bone imaging agent during a therapeutic trial [abstract]. J Nucl Med. 1991;32(suppl):918P.
48. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer. 1991;27:1085-1086.
49. Collins C, Eary JF, Donaldson G, et al. Samarium-153 EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993;34:1839-1844.
50. Turner JH, Martindale AA, Sorby P, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastases. Eur J Nucl Med. 1989;15:784-795.
51. Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol. 1989;7:1926-1931.
52. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574-1581.
53. Resche I, Chatal JF, Pecking A, et al. A dose-controlled study of Sm-153 ethylenediaminetetramethylene phosphonate in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33:1583-1591.
54. Bushnell D, Quick D, Reid R, et al. Multiple administration of Sm-153 lexidronam in the treatment of painful bone metastases [abstract]. J Nucl Med. 1996;37(suppl):31P.
55. Serafini AN. Therapy of metastatic bone pain. J Nucl Med. 2001;42:895-906.
56. Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylenediaminetetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002;20:1953-1954.
57. Srivastava SC, Meinken GE, Richards P, et al. The development and in vivo behavior of tin-containing radiopharmaceuticals I: chemistry, preparation and biodistribution in small animals. Int J Nucl Med Biol. 1985;12:167-174.
58. 117mSn (4+) diethylenetriamine pentaacetic acid for radionuclide therapy of bone cancer. J Nucl Med. 2000;41:2043-2050.
59. Krishnamurthy GT, Swailem FM, Srivastava SC, et al. Tin-117m(4+)DTPA: pharmacokinetics and imaging characteristics in patients with metastatic bone pain. J Nucl Med. 1997;38:230-237.
60. Atkins HL, Mausner LF, Srivastava SC, et al. Biodistribution of Sn-117m(4+)DTPA for palliative therapy of painful osseous metastases. Radiology. 1993;186:279-283.
61. Srivastava SC, Atkins HL, Krishnamurthy GT, et al. Treatment of metastatic bone pain with tin-117m stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. Clin Cancer Res. 1998;4:61-68.
62. 89Sr in mice. J Nucl Med. 2003;44:252-259.
63. 186Re-HEDP? Nucl Med Commun. 1999;20:833-836.
64. Silberstein EB. Systemic radiopharmaceutical therapy of painful osteoblastic metastases. Semin Radiat Oncol. 2000;10:240-249.
65. Fuster D, Herranz R, Alcover J, Mareos, et al. Treatment of metastatic bone pain with repeated doses of strontium-89 in patients with prostate neoplasm. Rev Exp Nucl Med. 2000;19:270-274.
66. Paszkowski AL, Hewitt DJ, Taylor A Jr. Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate. Clin Nucl Med. 1999;24:852-854.
67. Kossman SE, Weiss MA. Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate. Cancer. 2000;88:620-624.
68. Hoskin PJ, Ford HT, Harmer CL. Hemibody irradiation for metastatic bone pain in two histologically distinct groups of patients. Clin Oncol. 1989;1:67-69.
69. Weichselbaum RR, Hallahan D, Fuks Z, Kufe D. Radiation induction of immediate early genes: effectors of the radiation stress response. Int J Radiat Oncol Biol Phys. 1994;30:229-234.
70. Papatheofanis FJ. Serum PCIP as a bone formation marker in Sr-89 and external beam radiotherapy of prostatic bony metastases. Br J Radiol. 1997;70:594-598.
71. Papatheofanis FJ. Quantitation of biochemical markers of bone resorption following strontium-89 chloride therapy for metastatic prostatic carcinoma. J Nucl Med. 1997;38:1175-1179.
72. 89Sr-chloride therapy for metastatic prostate cancer bone pain. J Nucl Med. 2000;41:1021-1024.
73. Buffa F, Flux GD, Guy MJ, et al. A model-based method for the prediction of whole body absorbed dose and bone marrow toxicity for Re-186 HEDP treatment of skeletal metastases from prostate cancer. Eur J Nucl Med Mol Imaging. 2003;30:1114-1124.
74. Cameron PJ, Klemp PF, Martindale AA, Turner JH. Prospective Sm-153 EDTMP dosimetry by whole body scintigraphy. Nuc Med Commun. 1999;20:609-615.
75. Lin DL, Tarnowski CP, Zhang J, et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. The Prostate. 2001;47:212-221.